AVEO Pharmaceuticals (STU:VPA1) Institutional Ownership : 18.91% (As of Jun. 07, 2024)

View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AVEO Pharmaceuticals's institutional ownership is 18.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AVEO Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AVEO Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.70%.

AVEO Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for AVEO Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Institutional Ownership Chart

AVEO Pharmaceuticals Historical Data

The historical data trend for AVEO Pharmaceuticals can be seen below:

	2022-03-31	2022-04-30	2022-05-31	2022-06-30	2022-07-31	2022-08-31	2022-09-30	2022-10-31	2022-11-30	2022-12-31
Institutional Ownership	10.22	9.70	9.71	13.72	13.21	14.39	14.81	16.86	18.85	18.91

AVEO Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

AVEO Pharmaceuticals (STU:VPA1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines